Science and Research

A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer

This phase 2 portion of a phase 1/2 study examined the efficacy and safety of LY2603618, a selective checkpoint kinase 1 inhibitor, combined with pemetrexed and cisplatin (LY+Pem+Cis) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC). This multicenter, randomized, controlled, open-label study (NCT01139775) enrolled patients with stage IV nonsquamous NSCLC and an Eastern Cooperative Oncology Group performance status
  • Wehler, T.
  • Thomas, M.
  • Schumann, C.
  • Bosch-Barrera, J.
  • Vinolas Segarra, N.
  • Dickgreber, N. J.
  • Dalhoff, K.
  • Sebastian, M.
  • Corral Jaime, J.
  • Alonso, M.
  • Hynes, S. M.
  • Lin, J.
  • Hurt, K.
  • Bence Lin, A.
  • Calvo, E.
  • Paz-Ares, L.
  • Keywords

    • Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
    • Carcinoma, Non-Small-Cell Lung/*drug therapy/mortality/*pathology
    • Checkpoint Kinase 1/antagonists & inhibitors
    • Cisplatin/administration & dosage
    • Disease Progression
    • Female
    • Humans
    • Induction Chemotherapy
    • Kaplan-Meier Estimate
    • Lung Neoplasms/*drug therapy/mortality/*pathology
    • Maintenance Chemotherapy
    • Male
    • Pemetrexed/administration & dosage
    • Phenylurea Compounds/administration & dosage
    • Pyrazines/administration & dosage
    • Treatment Outcome
    • *Checkpoint kinase 1
    • *Cisplatin
    • *ly2603618
    • *Non-small cell lung cancer
    • *Pemetrexed
    Publication details
    DOI: 10.1016/j.lungcan.2017.03.001
    Journal: Lung cancer (Amsterdam, Netherlands)
    Pages: 212-216 
    Work Type: Original
    Location: Assoziierter Partner, ARCN, TLRC
    Disease Area: LC
    Partner / Member: UKSH (Lübeck), Thorax
    Access-Number: 28625637
    See publication on PubMed

    DZL Engagements

    chevron-down